479 related articles for article (PubMed ID: 16815314)
1. beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension.
Liu J; Liu ZQ; Yu BN; Xu FH; Mo W; Zhou G; Liu YZ; Li Q; Zhou HH
Clin Pharmacol Ther; 2006 Jul; 80(1):23-32. PubMed ID: 16815314
[TBL] [Abstract][Full Text] [Related]
2. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol.
Johnson JA; Zineh I; Puckett BJ; McGorray SP; Yarandi HN; Pauly DF
Clin Pharmacol Ther; 2003 Jul; 74(1):44-52. PubMed ID: 12844134
[TBL] [Abstract][Full Text] [Related]
3. Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol.
Liu J; Liu ZQ; Tan ZR; Chen XP; Wang LS; Zhou G; Zhou HH
Clin Pharmacol Ther; 2003 Oct; 74(4):372-9. PubMed ID: 14534524
[TBL] [Abstract][Full Text] [Related]
4. beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure.
Terra SG; Pauly DF; Lee CR; Patterson JH; Adams KF; Schofield RS; Belgado BS; Hamilton KK; Aranda JM; Hill JA; Yarandi HN; Walker JR; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2005 Mar; 77(3):127-37. PubMed ID: 15735607
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphisms of beta1 adrenergic receptor and their influence on the cardiovascular responses to metoprolol in a South Indian population.
Mahesh Kumar KN; Ramu P; Rajan S; Shewade DG; Balachander J; Adithan C
J Cardiovasc Pharmacol; 2008 Nov; 52(5):459-66. PubMed ID: 19033826
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
7. Discordant beta-blocker effects on clinic, ambulatory, resting, and exercise hemodynamics in patients with hypertension.
Beitelshees AL; Zineh I; Yarandi HN; Pauly DF; Johnson JA
Pharmacotherapy; 2006 Sep; 26(9):1247-54. PubMed ID: 16945046
[TBL] [Abstract][Full Text] [Related]
8. Influence of phenotype and pharmacokinetics on beta-blocker drug target pharmacogenetics.
Beitelshees AL; Zineh I; Yarandi HN; Pauly DF; Johnson JA
Pharmacogenomics J; 2006; 6(3):174-8. PubMed ID: 16402084
[TBL] [Abstract][Full Text] [Related]
9. The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects.
O'Shaughnessy KM; Fu B; Dickerson C; Thurston D; Brown MJ
Clin Sci (Lond); 2000 Sep; 99(3):233-8. PubMed ID: 11787477
[TBL] [Abstract][Full Text] [Related]
10. [The relationship between the gene polymorphism of TGF-beta1 and early renal injury in patients with essential hypertension, and the effect of the gene polymorphism of TGF- beta1 on the individual treatment with valsartan].
Zhao C; Wang YY; Xiao ZX; Wang YP; Zhang QY
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Aug; 24(4):428-31. PubMed ID: 17680535
[TBL] [Abstract][Full Text] [Related]
11. Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure.
Lobmeyer MT; Gong Y; Terra SG; Beitelshees AL; Langaee TY; Pauly DF; Schofield RS; Hamilton KK; Herbert Patterson J; Adams KF; Hill JA; Aranda JM; Johnson JA
Pharmacogenet Genomics; 2007 Apr; 17(4):277-82. PubMed ID: 17496726
[TBL] [Abstract][Full Text] [Related]
12. Beta1-adrenergic receptor polymorphisms and clinical efficacy of betaxolol hydrochloride in normal volunteers.
Schwartz SG; Puckett BJ; Allen RC; Castillo IG; Leffler CT
Ophthalmology; 2005 Dec; 112(12):2131-6. PubMed ID: 16325708
[TBL] [Abstract][Full Text] [Related]
13. Age and responses to isometric exercise in hypertension: possible predictors of the antihypertensive effect of diuretics and beta-blockers.
Corea L; Valori C; Bentivoglio M; Verdecchia P; Bichisao E
Int J Clin Pharmacol Ther Toxicol; 1985 Oct; 23(10):554-9. PubMed ID: 2866164
[TBL] [Abstract][Full Text] [Related]
14. Job strain, job demands and adrenergic beta1-receptor-polymorphism: a possible interaction affecting blood pressure in men.
Ohlin B; Berglund G; Nilsson PM; Melander O
J Hypertens; 2008 Aug; 26(8):1583-9. PubMed ID: 18622236
[TBL] [Abstract][Full Text] [Related]
15. Beta2-adrenergic receptor polymorphisms and treatment-induced regression of left ventricular hypertrophy in hypertension.
Iaccarino G; Izzo R; Trimarco V; Cipolletta E; Lanni F; Sorriento D; Iovino GL; Rozza F; De Luca N; Priante O; Di Renzo G; Trimarco B
Clin Pharmacol Ther; 2006 Dec; 80(6):633-45. PubMed ID: 17178264
[TBL] [Abstract][Full Text] [Related]
16. Impact of beta-blockers on sleep in patients with mild hypertension: a randomized trial between nebivolol and metoprolol.
Yilmaz MB; Erdem A; Yalta K; Turgut OO; Yilmaz A; Tandogan I
Adv Ther; 2008 Sep; 25(9):871-83. PubMed ID: 18758699
[TBL] [Abstract][Full Text] [Related]
17. Contrasting renal haemodynamic responses to the angiotensin converting enzyme inhibitor enalapril and the beta-adrenergic antagonist metoprolol in essential hypertension.
O'Connor DT; Mosley CA; Cervenka J; Bernstein KN
J Hypertens Suppl; 1984 Dec; 2(2):S89-92. PubMed ID: 6100882
[TBL] [Abstract][Full Text] [Related]
18. Combined beta 1-adrenoceptor blockade and/or beta 2- or beta 1/2 adrenoceptor stimulation as treatment of essential hypertension.
Schulte KL; Meyer-Sabellek W; Thiede HM; Röcker L; Gotzen R
J Hypertens Suppl; 1988 Dec; 6(4):S658-61. PubMed ID: 2853764
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of the antihypertensive effects of bopindolol and metoprolol in the treatment of arterial hypertension].
Bagatin J; Kuzmanić A; Rumboldt Z; Mirić D; Naranca M; Obad M; Pivac N; Polić S; Rakić D
Med Pregl; 1990; 43(3-4):145-8. PubMed ID: 1978233
[TBL] [Abstract][Full Text] [Related]
20. Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy.
Magnusson Y; Levin MC; Eggertsen R; Nyström E; Mobini R; Schaufelberger M; Andersson B
Clin Pharmacol Ther; 2005 Sep; 78(3):221-31. PubMed ID: 16153393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
